{"prompt": "['Alliance A221701', 'Drug accountability logs must be kept for the dexamethasone 0.5 mg/5 mL oral solution and the', 'ORA-Sweet\u00ae oral solution.', 'Formulation', 'Dexamethasone oral solution 0.5 mg/5mL is a dye-free, sugar-free solution with a cherry brandy', 'flavor. The solution contains citric acid, disodium edetate, flavoring, glycerin, methylparaben,', 'propylene glycol, propylparaben, sorbitol and water.', 'Administration', 'Dexamethasone/placebo will be administered at a dosage of 10 mL four times daily. Patients', 'should be instructed to swish the solution in their mouth for two minutes. They should not eat', 'or drink anything for thirty minutes before each mouthwash and at least one hour after each', 'mouthwash.', 'Pharmacokinetics', 'Onset of action: Prompt', 'Duration of metabolic effect: 72 hours', 'Metabolism: Hepatic', 'Half-life elimination: Normal renal function: 4 0.9 hours; Biological half-life: 36-54 hours', 'Time to peak, serum: Oral: 1-2 hours', 'Excretion: Urine (~10%)', 'Drug Interactions', 'Substrate of CYP3A4 (major), P-glycoprotein/ABCB1; Induces CYP2A6 (weak/moderate),', '2C9 (weak/moderate), 3A4 (weak), UGT1A1', 'Increased Effect/Toxicity: Aprepitant, azole antifungals, calcium channel blockers,', 'cyclosporine, estrogens, and macrolides may increase the serum levels of corticosteroids.', 'Corticosteroids may increase the hypokalemic effects of amphotericin B or potassium-wasting', 'diuretics (loop or thiazide); monitor. Refer to the package insert for a listing of other drugs.', 'Decreased Effect: Antacids and bile acid sequestrants may reduce the absorption of', 'corticosteroids; may reduce the absorption of corticosteroids; separate administration by 2', 'hours. Aminoglutethimide, barbiturates, and CYP3A4 inducers may reduce the serum', 'levels/effects of dexamethasone and dexamethasone may decrease the levels/effects of other', 'CYP3A4 substrates. Serum concentrations of isoniazid may be decreased by corticosteroids.', 'Corticosteroids may lead to a reduction in warfarin effect. Corticosteroids may suppress the', 'response to vaccinations.', 'Ethanol/Nutrition/Herb Interactions:', 'Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).', 'Food: Dexamethasone interferes with calcium absorption. Limit caffeine.', \"Herb/Nutraceutical: Avoid cat's claw, Echinacea (have immunostimulant properties)\", 'Adverse Events', 'Known potential adverse events: Consult the package insert for the most current and complete', 'information.', 'Common known potential toxicities, frequency not defined:', '37', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', 'Fluid and electrolyte disturbances, congestive heart failure in susceptible persons, hypertension,', 'euphoria, personality changes, insomnia, exacerbation of infection, exacerbation or symptoms', 'of diabetes, psychosis, muscle weakness, osteoporosis, vertebral compression fractures,', 'pancreatitis, esophagitis, peptic ulcer, dermatologic disturbances, convulsions, vertigo and', 'headache, endocrine abnormalities, ophthalmic changes, and metabolic changes. Some patients', 'have experienced itching and other allergic, anaphylactic or hypersensitivity reactions.', 'Withdrawal from prolonged therapy may result in symptoms including fever, myalgia and', 'arthralgia.', 'Storage and Stability', 'Store at Controlled Room Temperature, 20-25\u00b0C (68\u00b0-77\u00b0F); excursions permitted to 15-30\u00b0C', '(59-86\u00b0F).', '10.1.1 Nursing Guidelines', '1.', 'For this protocol dose to be used is 10cc which converts to two teaspoons for patients.', '2.', 'Instruct patients to shake solution well before use.', '3.', 'Patients should have a clean mouth before using the rinse, no eating for 30 min prior', 'to use.', '4. Two teaspoons should be swished in the mouth for two minutes then spit out; do not', 'swallow.', '5.', 'Patients should refrain from eating or drinking for one hour after rinsing.', '6.', 'Patients should refrain from eating foods with high acid content, and limit alcohol and', 'caffeine intake, as these food items can irritate the mouth further.', '7.', 'Monitor regularly for hypertension, CHF and other evidence of fluid retention.', '8.', 'Advise patient of possible mood or behavioral changes, i.e., depression, euphoria,', 'insomnia, even psychosis. Instruct patient to report any suspected changes to', 'healthcare team.', '9.', 'Assess for symptoms of gastric ulcer, heartburn, or gastritis. Suggest antacids.', 'Instruct patient to report symptoms to healthcare team if unable to control.', '10. Evaluate for signs and symptoms of throat candida infection (thrush), and treat', 'appropriately.', '11. Monitor blood glucose frequently especially if diabetic.', '12. Instruct patient to report frequent, unrelenting headaches or visual changes to', 'healthcare team.', '13. Advise patient that easy bruising is a side effect.', '10.2 Placebo Oral Solution', 'The placebo for this study will be ORA-Sweet\u00ae. This is a berry citrus flavored (contains FD&C', 'Red #40) inert syrup vehicle. The ORA-Sweet\u00ae contains purified water, sucrose, glycerin, and', 'sorbitol. It is buffered with citric acid and sodium phosphate, and preserved with methylparaben', 'and potassium sorbate.', '38', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}